SCHEMBL16633836

SCHEMBL16633836

O=C(O)C=Cc1ncc(Br)cn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF2AK2 P19525 1/20 0.44
CSNK2A2 P19784 1/20 0.44
CSNK2B P67870 1/20 0.44
CSNK2A1 P68400 1/20 0.44
P4HTM Q9NXG6 1/20 0.42
KDM4E B2RXH2 4/20 0.40
CYP3A4 P08684 2/20 0.40
BLM P54132 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 1/20 0.40
ALDH1A1 P00352 3/20 0.39
HCAR2 Q8TDS4 5/20 0.39
HDAC3 O15379 2/20 0.39
HDAC4 P56524 2/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC7 Q8WUI4 2/20 0.39
HDAC2 Q92769 2/20 0.39
HDAC10 Q969S8 2/20 0.39
HDAC11 Q96DB2 2/20 0.39
HDAC8 Q9BY41 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16633834 1.00 EIF2AK2 (0.44) EIF2AK2CSNK2A2CSNK2BCSNK2A1P4HTM
SCHEMBL1914087 0.76 KDM4E (0.50) EIF2AK2CSNK2A2CSNK2BCSNK2A1P4HTM
SCHEMBL1914082 0.76 KDM4E (0.50) EIF2AK2CSNK2A2CSNK2BCSNK2A1P4HTM
SCHEMBL1368017 0.76 HCAR2 (0.48) EIF2AK2CSNK2A2CSNK2BCSNK2A1P4HTM
SCHEMBL1368018 0.76 HCAR2 (0.48) EIF2AK2CSNK2A2CSNK2BCSNK2A1P4HTM
SCHEMBL21001958 0.75 THRB (0.53) CSNK2A2CSNK2BCSNK2A1P4HTMKDM4E
SCHEMBL5585151 0.74 KDM4E (0.42) EIF2AK2CSNK2A2CSNK2BCSNK2A1P4HTM
SCHEMBL2195182 0.73 NPC1 (0.33) CYP3A4ALDH1A1RAB9ASMN1; SMN2ESR1
SCHEMBL2195175 0.73 NPC1 (0.33) CYP3A4ALDH1A1RAB9ASMN1; SMN2ESR1
SCHEMBL16634172 0.71 MIF (0.39) EIF2AK2CSNK2A2CSNK2BCSNK2A1P4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2828243-B1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS INC (US) 2018-10-17 EP disclosed
US-9499538-B2 Estrogen receptor modulators and uses thereof SERAGON PHARMACEUTICALS, INC. (US) 2016-11-22 US disclosed
US-20150105403-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF SERAGON PHARMACEUTICALS, INC. 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105403-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ESR2, ESRRG, GPER1 EIF2AK2 2429/4885CSNK2A2 788/4885CSNK2B 912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.